Burrill & Company Announces Second Close of Burrill Capital Fund IV, L.P.

Burrill & Company Announces Second Close of Burrill Capital Fund IV, L.P.

SAN FRANCISCO, CA, Aug 02, 2012 (MARKETWIRE via COMTEX) -- Burrill & Company today announced a second close of its Burrill Capital Fund IV, L.P., bringing the aggregate capital commitments to $505 million.

The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, healthcare delivery, wellness, and digital health.

"We are pleased that our new fund generated strong interest among investors," says G. Steven Burrill, CEO of Burrill & Company, a global life sciences financial services firm. "This is a time of great opportunities globally for investors in the life sciences, not just in traditional sectors, but emerging areas brought about by the convergence of healthcare and information technology."

About Burrill & Company Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com .

 

       
        Contact:
        Daniel Levine
        Managing Director
        Burrill & Company
        Email Contact
        415-591-5449
       
       
        SOURCE: Burrill & Company

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.